627 EVEREST-2: a seamless phase 1/2 study of A2B694, a logic-gated Tmod CAR T-cell therapy, in patients with mesothelin-expressing solid tumors with human leukocyte antigen-A*02 loss of heterozygosity
Regular and Young Investigator Award Abstracts | November 5, 2024 | Volume: No volume available | Issue: No issue available | Pages: A721-A722
10.1136/jitc-2024-sitc2024.0627